References
- Chung, W. G. Effect of age and smoking on in vivo CYP1A2, flavin-containing monooxygenase, and xanthine oxidase activities in Koreans: Determination by caffeine metabolism. Clin Pharmacol Ther 67: 258-266 (2000) https://doi.org/10.1067/mcp.2000.104617
- Sesardic, D., Boobis, A. R., Edwards, R. J. & Davies, D. S. A form of cytochrome P450 in man, orthologous to form d in the rat, catalyses the O-deethylation of phenacetin and inducible by cigarette smoking. Br J Clin Pharmacol 26:363-372 (1988) https://doi.org/10.1111/j.1365-2125.1988.tb03393.x
- Butler, M. A., Iwasaki, M., Guengerich, F. P. & Kadlubar, F. F. Human cytochrome P-450A (P-450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and Noxidation of carcinogenic arylamines. Proc Natl Acad Sci USA. 86:7696-7700 (1989)
- Nakajima, M. et al. Genetic polymorphism in the 5′- flanking region of human CYP1A2 gene: Effect on the CYP1A2 inducibility in humans. J Biochem 125:803-808 (1999) https://doi.org/10.1093/oxfordjournals.jbchem.a022352
- Chida, M. et al. Detection of three genetic polymorphisms in the 5′-flanking region and intron 1 of human CYP1A2 in the Japanese population. Jpn J Cancer Res 90:899-902 (1999) https://doi.org/10.1111/j.1349-7006.1999.tb00832.x
-
Sachse, C., Brockmoller, J., Bauer, S. & Roots, I. Functional significance of a C
$\rightarrow$ A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449 (1999) https://doi.org/10.1046/j.1365-2125.1999.00898.x - Han, X. M. et al. Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2. Pharmacogenetics 11:429-435 (2001) https://doi.org/10.1097/00008571-200107000-00006
- Sachse, C. et al. Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism. Br J Clin Pharmacol 55:68-76 (2003) https://doi.org/10.1046/j.1365-2125.2003.01733.x
- Ghotbi, R. et al. Comparisons of CYP1A2 genetic polymorphisms, enzyme activity and the genotypephenotype relationship in Swedes and Koreans. Eur J Clin Pharmacol 63:537-546 (2007) https://doi.org/10.1007/s00228-007-0288-2
- Han, X. M. et al. Inducibility of CYP1A2 by omeprazole in vivo related to the genetic polymorphism of CYP1A2. Br J Clin Pharmacol 54:540-543 (2002) https://doi.org/10.1046/j.1365-2125.2002.01686.x
- Mihara, K. et al. Effects of genetic polymorphism of CYP1A2 inducibility on the steady-state plasma concentrations of trazodone and its active metabolite mchlorophenylpiperazine in depressed Japanese patients. Pharmacol Toxicol 88:267-270 (2001) https://doi.org/10.1034/j.1600-0773.2001.d01-115.x
- Nakajima, M. et al. Phenotyping of CYP1A2 in Japanese population by analysis of caffeine urinary metabolites: absence of mutation prescribing the phenotype in the CYP1A2 gene. Cancer Epidemiol Biomarkers Prev 3:413-421 (1994)
- Bae, S. Y. et al. Effects of genetic polymorphisms of MDR1, FMO3 and CYP1A2 on susceptibility to colorectal cancer in Koreans. Cancer Sci 97:774-779 (2006) https://doi.org/10.1111/j.1349-7006.2006.00241.x
- Moonen, H., Engels, L., Kleinjans, J. & Kok, T. The CYP1A2-164A¤C polymorphism (CYP1A2*1F) is associated with the risk for colorectal adenomas in humans. Cancer Lett 229: 25-31 (2005) https://doi.org/10.1016/j.canlet.2004.12.010